ライフサイエンスコーパス: trough

1 to tropical cyclones and atmospheric lows or troughs).

2 the air-water interface in a conical Teflon trough.

3 enge performed after first and last doses at trough.

4 m for the impending megaquake at the Nankai Trough.

5 sited on lung surfactant films in a Langmuir trough.

6 ult at shallow depths (~ 8 km) in the Nankai Trough.

7 harpness of the beta peaks compared with the troughs.

8 ics, including seasonality, abrupt peaks and troughs.

9 surface topography such as the formation of troughs.

10 e temporal pattern of intermittent peaks and troughs.

11 l maxima, called "domes", separated by steep troughs.

12 k: 27.2 +/- 10.2 min; P = 0.0017; applied at trough: 64.6 +/- 6.5 min, P < 0.0001).

13 resections necessitate a long learning curve trough a stepwise fulfillment of difficulties.

14 ments and Main Results: DD therapy increased trough AAT levels to normal and, compared with SD therap

15 ogic evaluation included assessment of serum trough adalimumab and antibodies against adalimumab (AAA

16 rmanent AAA was associated with undetectable trough adalimumab levels and worse uveitis outcome.

17 In all patients with permanent AAA+, trough adalimumab levels became undetectable (P < 0.001)

18 Median trough adalimumab serum levels were higher in responders

19 glucose trough, and steeper slope to glucose trough after glipizide.

20 raphic positions (polygon centers, rims, and troughs) along the permafrost degradation gradient, we m

21 obe exclusion of 92 +/- 10% (mean +/- SD) at trough and 96 +/- 9% at peak (both p < 10(-12) vs. place

22 Peak, trough and final viscosities, breakdown and setbacks dec

23 istics showed that peak and final viscosity, trough and setback value, and breakdown of RB was lower

24 explanation for enhanced transmission during troughs and an associated seasonal monsoon response in t

25 MEP amplitude was facilitated during troughs and rising flanks, but no phasic suppression was

26 area over the curve, shorter time to glucose trough, and steeper slope to glucose trough after glipiz

27 impact melts with scattered endogenic pits, troughs, and bright mounds indicative of outgassing of v

28 orts, tropical cyclones, atmospheric lows or troughs, and melting snow.

29 iles were processed to enhance the peaks and troughs, and then an exclusion or inclusion criterion ba

30 6780 patients with data available) and mean trough anti-FXa activity (0.35-0.85 IU/mL in 2865 patien

31 s glaciomarine and Holocene sediments in the troughs apparently limit seepage.

32 ediments as patches on the up-flow limbs and trough areas between these ridges forming the Striated U

33 n, most notably characterized by an activity trough at dusk followed by a high level of male courtshi

34 s applied during the transition from peak to trough Bmal1 expression induced a phase advance (49.8 +/

35 Contractions applied at peak or trough Bmal1 expression induced significant phase delays

36 These values are close to the steady state trough brain concentration of methylthioninium ion (0.18

37 e they do occur, the resulting deep epidemic troughs break the chain of transmission, leading to epid

38 Median trough BTK occupancy at steady state was 97%.

39 imary outcome was model-derived steady-state trough C1-INH functional activity.

40 hielding provided stronger apoptotic effects trough caspase-3 activation compared to N2 shielding.

41 cant (p < .05) increases in seasonal peak-to-trough CO2 amplitude (AMPP-T ) at nine stations, and in

42 lm-coated tablets, the geometric mean (GM) C(trough) (coefficient of variation) was 0.32 mg/L (94%),

43 endpoints were overall response and maximum trough concentration (C(trough); cycle 3, day 1 pre-dose

44 -inferiority of the cycle 7 pertuzumab serum trough concentration (C(trough); ie, cycle 8 predose per

45 Only 1 patient showed a trough concentration (Ctrough) below the suggested targe

46 n SC dose that would yield a rituximab serum trough concentration (Ctrough) in the same range as that

47 BV/PTV/r + DSV + darunavir (DRV) lowered DRV trough concentration (Ctrough) levels.

48 both area under the curve (AUC0-28 days) and trough concentration (Ctrough, 28th day) of LA cabotegra

49 reduced using an algorithm to reach a target trough concentration (TC) of 3-7 mug/mL in all patients

50 ugh concentration from first to second dose (trough concentration = 0.822 and 1.23 ng/mL for weeks 1

51 for weeks 1 and 2, respectively, with 24 mg; trough concentration = 0.993 and 1.47 ng/mL for weeks 1

52 olimus clearance (daily tacrolimus dose [mg]/trough concentration [mug/L]) and biopsy-proven acute re

53 emission than reactive monitoring (measuring trough concentration after loss of response).

54 eek after transplantation nor time to target trough concentration between patients later experiencing

55 One-third of patients had an adalimumab trough concentration exceeding 7 mg/L.

56 5 days and approximately 50% accumulation of trough concentration from first to second dose (trough c

57 +/- 0.3 g/day and the individual median MPA trough concentration in the time period of anticipated c

58 -dose-fits-all"), to mycophenolic acid (MPA) trough concentration monitoring, to dose optimization to

59 t month 1 or in area under the curve0-4h and trough concentration when measured at months 3 and 6.

60 We evaluated mean TAC C0 (tacrolimus trough concentration) and TAC time in therapeutic range

61 us was calculated as the area under curve of trough concentrations (AUCtc).

62 Target dolutegravir trough concentrations (C(trough)) were based on referenc

63 study, and correlated with plasma ritonavir trough concentrations (C24).

64 Efavirenz trough concentrations (Cmin) were predicted using popula

65 Tacrolimus trough concentrations (mean/variability), as well as con

66 lected in the standard monitoring parameter, trough concentrations (P=0.80).

67 tive monitoring (physicians were informed of trough concentrations after loss of response, n = 40).

68 ound that proactive monitoring of adalimumab trough concentrations and adjustment of doses and interv

69 Proactive monitoring of drug trough concentrations and antibodies against drugs might

70 nd whole blood containing peak, midpoint, or trough concentrations and incubated for up to 120 hours

71 at 2 mg once daily and adjusted to maintain trough concentrations between 3-12 ng/mL through to day

72 However, whole blood trough concentrations commonly utilized in TDM are not s

73 one-third of patients, it was observed that trough concentrations exceeded the therapeutic window.

74 Similarly, median (IQR) time-averaged trough concentrations in breast milk were 3.3 ng/mL (2.3

75 creased proportionally up to 120 mg/day with trough concentrations in the in-vitro active range from

76 Trough concentrations increased less than proportionally

77 o groups that received proactive monitoring (trough concentrations measured at weeks 4 and 8 and then

78 Although non-trough concentrations might have underestimated the freq

79 rvals of adalimumab were adjusted to achieve trough concentrations of 5 mug/mL.

80 /20 (100%) of those with peak, midpoint, and trough concentrations of antipseudomonal agents, respect

81 apy might not be a direct function of plasma trough concentrations of C1 inhibitor.

82 of clinically meaningful peak, midpoint, and trough concentrations of meropenem, imipenem, cefepime,

83 The mean steady state peak and trough concentrations of rituximab were 461 mug/mL (SD 9

84 reached during cycle 3 with mean maximum and trough concentrations ranging from 419 mug/mL (geometric

85 e were no significant differences in neither trough concentrations the first week after transplantati

86 iolytic effect in subjects with SAD although trough concentrations with 25 mg once daily appeared to

87 Overall geometric mean ratio of trough concentrations with versus without rifapentine-is

88 The median proportion of tacrolimus trough concentrations within the target range was compar

89 emic exposure of tacrolimus, despite similar trough concentrations, may in the long run increase the

90 tles inoculated with the peak, midpoint, and trough concentrations, respectively (P </= 0.001).

91 24 (58%) of bottles with peak, midpoint, and trough concentrations, respectively (P = 0.221).

92 034) of those exposed to peak, midpoint, and trough concentrations, respectively.

93 ount (other covariates, including tacrolimus trough concentrations, were nonsignificant).

94 were found to be associated with tacrolimus trough concentrations.

95 observed only in the presence of antibiotic trough concentrations.

96 ic outcomes it is recommended to monitor IFX trough concentrations.

97 Predose (trough) concentrations of HTT(Rx) in CSF showed dose dep

98 ides non-inferior cycle 7 pertuzumab serum C(trough) concentrations to intravenous pertuzumab plus tr

99 re of basking white butterflies mimics the V-trough concentrator which is designed to increase solar

100 ently rapid kinetics and long-term stability trough continuous cycles of chemical transformation are

101 comparative study, 60 patients were selected trough convenience sampling.

102 response and maximum trough concentration (C(trough); cycle 3, day 1 pre-dose).

103 tacrolimus trough, variability of tacrolimus trough, de novo donor-specific antibody development, cyt

104 the presence of anti-drug antibodies and non-trough drug concentrations could predict treatment respo

105 ng and explores the performance of different trough drug concentrations for anti-tumor necrosis facto

106 ictive value of anti-drug antibodies and non-trough drug concentrations on treatment response (DeltaD

107 in a two-fold to three fold gradient of mean trough drug exposure (16.0-48.5 ng/mL in 6780 patients w

108 outbreaks and the intervening inter-epidemic trough during which fadeout of transmission was most lik

109 studied on the planar surface of a Langmuir trough, even though most physiological interfaces are cu

110 We assessed the efficacy and safety of two trough exposure concentrations of everolimus, 3-7 ng/mL

111 owing warm water guided by a deep continuous trough extending to the continental slope.

112 s: Exacerbations and change from baseline in trough FEV(1) and St.

113 lso maintained throughout the study for both trough FEV(1) and St.

114 (95% CI 10 to 70) and 60 mL (20 to 100) for trough FEV(1), -0.01 (-0.68 to 0.66) and 0.30 (-0.37 to

115 We modelled differences at week 52 in trough FEV(1), St George's Respiratory Questionnaire (SG

116 P = .27]), and the key secondary end point, trough FEV1 (5 mug, 87 mL [95% CI, 19-154; P = .01]; 2.5

117 The primary end point analyzed was change in trough FEV1 (DeltaFEV1) from baseline to 8 to 12 weeks o

118 imary endpoints were change from baseline in trough FEV1 and in St. George's Respiratory Questionnair

119 Significant improvements in trough FEV1 at week 24 (a secondary end point) were obse

120 ter improvements in the primary end point of trough FEV1 compared to salmeterol after 4 weeks of dosi

121 d within the first 3 h after evening dosing; trough FEV1 response; and responder rate assessed accord

122 Peak and trough FEV1 responses were significantly greater with ti

123 lmeterol group (all p<0.0001); difference in trough FEV1 was 146 mL (95% CI 105-188), 180 mL (138-221

124 the mammalian jaw hinge and the postdentary trough for mandibular attachment of the middle ear-a tra

125 Improvement in trough forced expiratory volume in 1 s (FEV1) and the in

126 administration, a dose-dependent increase in trough functional C1-INH activity was observed.

127 quency and magnitude of population peaks and troughs greatly impact the accuracy of our CC response m

128 toring strategy was significantly lower than trough-guided monitoring (OR, 0.68 [95% CI, .46-.99]).

129 Additional analysis compared AUC vs trough-guided monitoring on AKI incidence.

130 studies reported AKI associated with AUC- vs trough-guided monitoring.

131 Donors in the G6PDd group had lower trough hemoglobin in postoperative period (P = 0.006), g

132 e 7 pertuzumab serum trough concentration (C(trough); ie, cycle 8 predose pertuzumab concentration) w

133 fied as mild acute rejection correlates with troughs in immunosuppression and subsides when immunosup

134 oustic backscatter data from one of the deep troughs in the Amundsen Sea, Antarctica.

135 g/L (63%), which was 45% lower than the GM C(trough) in fasted adults.

136 g/L (48%), which was 54% lower than the GM C(trough) in fasted adults; and in those 30 kg to less tha

137 c inhibitory quotients were determined using trough INSTI plasma concentrations.

138 umab serum C(trough) subcutaneous to serum C(trough) intravenous was 1.22 (90% CI 1.14-1.31).

139 As the water in the trough is drained, the monolayer is deposited on a suppo

140 who received enoxaparin adjusted by anti-Xa trough level (adjustment group) were compared with those

141 3), and BUN (P=0.05), and blood cyclosporine trough level (C0, P=0.005) were independently associated

142 Mean TAC trough level (Cmin), used to adjust daily dose, was not

143 Patients received EVL (target trough level (Ctrough, 3-8 ng/mL), prednisone, and tacro

144 Adalimumab trough level and PASI score at the time of serum samplin

145 ine whether targeting a prophylactic anti-Xa trough level by adjusting the enoxaparin dose would redu

146 Similar to younger recipients TAC trough level has also a high correlation (R = 0.76) with

147 sodium is dosed by anti-factor Xa (anti-Xa) trough level is not well described.

148 Patients with a trough level of 0.1 IU/mL or lower received enoxaparin s

149 No correlation between ribavirin trough level on day 7 or at month 2 with a virological r

150 Sirolimus remained > 5 mug/L, the trough level used in oral immunosuppressive therapy, for

151 Imatinib plasma trough level was performed at day 22 and if <1000 ng/mL,

152 roviding 3 adjusted doses of enoxaparin, the trough level was redrawn and the dosage was adjusted as

153 ightly, adjusted according to serum anti-HBs trough level) if they were HBsAg- and HBV-DNA negative a

154 urin inhibitor dose according to whole blood trough level, even though it overestimates the effective

155 achieved sustained Abeta reduction of 80% at trough level.

156 ic kidney recipients to a control group with trough-level monitoring of immunosuppressants or to an i

157 ants who maintained everolimus time-averaged trough levels >5 ng/mL during the first 2 months of ther

158 dnDSA had a higher proportion of tacrolimus trough levels <5 ng/ml, which continued to be significan

159 and 2927 mg/y [IQR, 2377 to 3667 mg/y]) and trough levels (4.2 microg/mL [IQR, 2.6 to 5.8 microg/mL]

160 hich correlated with undetectable adalimumab trough levels (P = 0.014).

161 s observed between AAA titers and adalimumab trough levels (P = 0.2).Concomitant immunosuppression di

162 IS was defined as a median of Tac, CsA blood trough levels 12 hours after drug administration, or blo

163 was considered as a median of Tac, CsA blood trough levels 12 hours after drug administration, or blo

164 ther everolimus or sirolimus, n = 33, target trough levels 3-8 ng/mL).

165 either everolimus or sirolimus, n=33, target trough levels 3-8 ng/ml).

166 and 24 h after reperfusion), and tacrolimus (trough levels 8-12 ng/mL) was used for maintenance immun

167 Tacrolimus trough levels along the first year were not different be

168 Tacrolimus trough levels along the first year were not different be

169 s were not correlated with immunosuppressive trough levels and a selective increase was not observed

170 ombination therapies including MMF, at serum trough levels and higher, are toxic for the human bronch

171 Tacrolimus trough levels and laboratory values were closely monitor

172 nDSA) development correlates with tacrolimus trough levels and the recipient's individualized alloimm

173 that HLA-DR/DQ eplet mismatch and tacrolimus trough levels are independent predictors of dnDSA develo

174 Mean trough levels at week 24 in the IV infusion series of 30

175 sttransplant year, with (1) at least 3 blood trough levels available to calculate coefficient of vari

176 initiated, the TAC dosage was skipped until trough levels began to decline; it was then administered

177 We analyzed the frequency of tacrolimus trough levels below a series of thresholds <6 ng/ml and

178 bulation), hospital discharge before initial trough levels could be drawn, or incorrect timing of tro

179 ant recipients with 50,011 serial tacrolimus trough levels had HLA-DR/DQ eplet mismatch determined us

180 Mean tacrolimus trough levels in the 6 months before dnDSA development w

181 ariable analysis, high calcineurin inhibitor trough levels in the month before diagnosis (odds ratio

182 Trough levels increased from 45 to 132 ng/ml (P<0.001).

183 ther increased to 6045 ng h/ml (P=0.03), and trough levels increased to 218 ng/ml (P=0.03), above the

184 The C1-INH trough levels increased with C1-INH treatment.

185 A therapeutic range of adalimumab trough levels of 3.51 mg/L to 7.00 mg/L, which correspon

186 g at 3mg/m(2) /day (titrated to target blood trough levels of 5-15ng/ml).

187 losporin A, resulting in significantly lower trough levels of everolimus (3.5 versus 4.5 ug/L, P<0.00

188 Patients were closely monitored for trough levels of immunosuppressive agents, laboratory va

189 Pronounced elevations in trough levels of nitric oxide metabolites occurred with

190 Overall, 97% of all trough levels of nonallergic patients were > 100 IU/L.

191 oup (23% versus 15%, P = 0.04) due to higher trough levels of Tacrolimus on month 3 (9.48 versus 7.30

192 mes compared with BSX and could permit lower trough levels of Tacrolimus, thus reducing occurrence of

193 Time-averaged everolimus trough levels significantly correlated with greater inhi

194 Higher DIN trough levels were associated with response.

195 Deviations in trough levels were avoided, thus preventing any clinical

196 ance: In this study, subprophylactic anti-Xa trough levels were common in trauma patients.

197 Baseline characteristics and mean tacrolimus trough levels were comparable between arms.

198 Overall, adalimumab trough levels were higher in responder patients.

199 Exposures: Anti-Xa trough levels were monitored in patients in the adjustme

200 Tacrolimus trough levels were readily achieved posttransplant; init

201 te the biological effects of normalizing AAT trough levels with double-dose (DD) therapy (120 mg/kg/w

202 Therapeutic monitoring is based on mTORi trough levels, which do not necessarily reflect biologic

203 assessed by self-report or SD of tacrolimus trough levels.

204 tacept with lowered tacrolimus and sirolimus trough levels.

205 us were necessary for maintaining sufficient trough levels.

206 evels could be drawn, or incorrect timing of trough levels.

207 with lower Tac, but not CsA, dose-normalized trough levels.

208 is clinically useful even in the absence of trough levels.

209 ll P<0.001) but did not correlate with mTORi trough levels.

210 A and everolimus in the same target range of trough levels.

211 Vancomycin dosing did not influence initial trough levels; 78% were <10 ug/mL.

212 iggers a complete rearrangement of the open, trough-like ID structure through the ubiquitin of one pr

213 lthough the permeability of the sandy Nankai Trough materials are higher than that of the clayey mate

214 may determine whether a patient experiences trough-max or peak-max PAC, and the thalamus is a critic

215 determinant of whether the thalamus exhibits trough-max PAC, which is associated with lower propofol

216 ygon, coalescent low center polygon, polygon trough, meadow, ponds, rivers, and lakes, to determine t

217 months (IQR 6.5-9.3), overall response and C(trough) met the predefined non-inferiority criteria.

218 09 vancomycin consensus guidelines recommend trough monitoring as a surrogate marker for the target a

219 However, recent data suggest that trough monitoring is associated with higher nephrotoxici

220 in the peak month (April) compared with the trough month (November) (odds ratio, 1.24; 95% CI, 1.10-

221 30 m on the continental slope of the Rockall Trough, Northeast Atlantic, to compare changes in fracti

222 V-1 adaptation to VRC01 and an average VRC01 trough of 221 mug/mL.

223 ration (median, 38 ms) preferentially at the trough of both CA1 theta and slow irregular oscillations

224 suppression was systematically embedded in a trough of oscillations of contrast sensitivity that fluc

225 ing and slowing the dynamics of water at the trough of the binding site.

226 In contrast, ripples occurring at the trough of their SPWs relate to weaker neocortical up-reg

227 In contrast, phase-locking at the trough of theta followed fixations to novel object-locat

228 ormance when inhibition was triggered by the trough of theta.

229 it maximum alpha power at either the peak or trough of this SWO; this implies the thalamus may be the

230 g/L (94%), which was 61% lower than the GM C(trough) of 0.83 mg/L (26%) in fasted adults on dolutegra

231 On the basis of the deep absorption trough on the blue side of the Lyman-alpha emission line

232 s using the position of the signal peaks and troughs on longitudinal reflectivity profiles.

233 The formation of the monsoon trough over Indo-Gangetic plain during the active period

234 y pressurized fluid is greater at the Nankai Trough owing to higher friction, although initially over

235 The trueness of the methodology was assessed trough parallel samples analysis by ICP-MS.

236 argeted mutants of Rsn-2, using the Langmuir trough, pendant drop tensiometry, and circular dichroism

237 o, BI 749327 (30 mg/kg/day, yielding unbound trough plasma concentration ~180 nM) improves left heart

238 Antiretroviral trough plasma concentrations (C12h) were determined usin

239 hole blood containing the peak, midpoint, or trough plasma concentrations for meropenem, ceftolozane-

240 Geometric mean trough plasma concentrations were 0.302 mug/mL (95% CI 0

241 Concomitant high vancomycin trough plasma levels had been observed in each patient.

242 The mean trough plasma levels of C1-INH functional activity, C1-I

243 l tolerated by the patient with undetectable trough plasma levels of voriconazole.

244 r 60 mg bid achieved high levels of peak and trough platelet inhibition in nearly all patients, simil

245 On Bylot, ice-wedge trough ponds showed significantly higher MeHg (0.3-2.2 n

246 tion, played a major role in determining the trough positions of simulated binaural phase-response cu

247 nd permafrost samples from center, ridge and trough positions of water-saturated low-centered polygon

248 re found to in turn cluster ripples in their troughs, providing fine-tuned temporal frames for the hy

249 Dose adjustments were done to attain target trough ranges during a 6-week titration period, and as n

250 injection with CSL830 showed a lower peak-to-trough ratio and more consistent exposures.

251 ed pharmacokinetic profile of a high peak to trough ratio and short half-life in humans.

252 implications for dosing regimen and peak-to-trough ratio at the steady state.

253 n of the lead molecule 32 with a low peak-to-trough ratio.

254 molgus monkey that showed a very low peak-to-trough ratio.

255 del captures experimentally observed peak to trough ratios, relative abundances, and phase difference

256 initially overpressured fluid at the Nankai Trough restrains the fault weakening.

257 lpha waves at different phase angles (peaks, troughs, rising and falling flanks) and compared them to

258 PV was calculated from at least 5 tacrolimus trough samples obtained between months 6 and 18 after li

259 Non-fasting peak and trough samples of maternal plasma and breast milk were o

260 r the maternal DOT PrEP dose, while maternal trough samples were obtained at the end of the PrEP dosi

261 The primary endpoint was trough serum concentration at cycle five, with a non-inf

262 At cycle five, the geometric mean trough serum concentration in patients given subcutaneou

263 hilst at 19 microg.mL(-1) (a clinical target trough serum concentration), vancomycin was mainly monom

264 subcutaneous rituximab 1600 mg would achieve trough serum concentrations that were non-inferior to th

265 ide, subcutaneous rituximab 1600 mg achieved trough serum concentrations that were pharmacokineticall

266 standard dose (SD; 60 mg/kg/wk) elevates AAT trough serum levels to around 50% of normal; however, ou

267 acebo twice daily, with the dosage guided by trough serum levels.

268 Regarding to RVA results, peak, breakdown, trough, setback, and final viscosities of native starch

269 We obtained trough spot urine and plasma samples during a 6-week dir

270 g hippocampal ripples within their excitable troughs, stimulation in-phase with the slow oscillation

271 e geometric mean ratio of pertuzumab serum C(trough) subcutaneous to serum C(trough) intravenous was

272 to 120 degrees C hot sediments in the Nankai Trough subduction zone.

273 ecline from an observed peak to a subsequent trough, tends to severely overestimate the frequency and

274 Median (interquartile range) steady-state trough TFV concentrations (ng/mL) for perfect, moderate,

275 Trough TFV concentrations at steady state were significa

276 the organic-rich soils of polygon center and trough than the relatively drier ridge soils.

277 o reveal a temporal waveform with a peak and trough that correlates with a cardiac cycle as revealed

278 elements associate head-to-tail, creating a trough that cradles two c-di-AMP molecules making quasi-

279 amplitude (AMPP-T ) at nine stations, and in trough-to-peak amplitude (AMPT-P ) at eight stations ove

280 f neurons with intermediate spike durations (trough-to-peak approximately 350 mus after high-pass fil

281 13.0 to 250.0) for emtricitabine, reflecting trough-to-peak breast milk concentration ratios of 1.0 f

282 nofovir and emtricitabine (respective median trough-to-peak concentration ratio ~1), demonstrating th

283 In particular, tropical upper-tropospheric troughs (TUTTs), as part of the summertime stationary wa

284 loading, p.E161K carriers displayed a higher trough urinary pH (5.34 versus 4.89; P=0.01) than wild-t

285 All but one trough value was above the 90% maximal inhibitory concen

286 of the P1' cyclopropyl ring enhanced plasma trough values following oral administration to rats.

287 ur-fold improved AUC and eight-fold higher C(trough) values of 1 compared with oral administration of

288 usting for potential confounders (tacrolimus trough, variability of tacrolimus trough, de novo donor-

289 on of pyramidal cell assemblies at the theta trough via disinhibition.

290 Peak, breakdown and trough viscosity values of the amylose-lipid complexed s

291 ) of mRNA into immunodeficient mice maintain trough VRC01 levels above 40 mug ml(-1).

292 g taking 25 mg film-coated tablets, the GM C(trough) was 0.39 mg/L (48%), which was 54% lower than th

293 kg taking 35 mg film-coated tablets the GM C(trough) was 0.46 mg/L (63%), which was 45% lower than th

294 The geometric means ratio for C(trough) was 107.93% (90% CI 95.74-121.67), and the maxim

295 93% (90% CI 95.74-121.67), and the maximum C(trough) was 593 mug/mL (SD 306) in the subcutaneous grou

296 ated tablets or 30 mg dispersible tablets, C(trough) was close to the adult reference (with similar e

297 CNI dose and CNI trough were reduced by 20% and 8% (group A) versus 55% a

298 Correlograms with a peak or trough were taken as evidence for excitatory or inhibito

299 Subprophylactic anti-Xa troughs were noted in 73 of 87 patients (83.9%) in the a

300 Target dolutegravir trough concentrations (C(trough)) were based on reference adult pharmacokinetic d